Puma Biotechnology, Inc. SEC filings PBYI
Puma Biotechnology, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Oct 25, 2012. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 6, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Jun 11, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 7, 2026 | Jun 11, 2026 |
| DEFA14A | Additional proxy material | Apr 28, 2025 | — |
| DEF 14A | Proxy statement | Apr 28, 2025 | Jun 11, 2025 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 18, 2024 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | — |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 14, 2022 |
| DEFA14A | Additional proxy material | Apr 26, 2021 | — |
| DEF 14A | Proxy statement | Apr 26, 2021 | Jun 15, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 2, 2021 | Jun 15, 2021 |
| DEFA14A | Additional proxy material | Apr 27, 2020 | — |
| DEF 14A | Proxy statement | Apr 27, 2020 | Jun 9, 2020 |
| DEFA14A | Additional proxy material | Apr 29, 2019 | — |
| DEF 14A | Proxy statement | Apr 29, 2019 | Jun 10, 2019 |
| DEFA14A | Additional proxy material | Apr 30, 2018 | — |
| DEF 14A | Proxy statement | Apr 30, 2018 | Jun 12, 2018 |
| DEFA14A | Additional proxy material | Apr 28, 2017 | — |
| DEF 14A | Proxy statement | Apr 28, 2017 | Jun 12, 2017 |
| DEFA14A | Additional proxy material | Apr 29, 2016 | — |
| DEF 14A | Proxy statement | Apr 29, 2016 | Jun 13, 2016 |
| PRE 14A | Preliminary proxy statement | Apr 15, 2016 | Jun 13, 2016 |
| DEFA14A | Additional proxy material | Jan 27, 2016 | — |
| DEFA14A | Additional proxy material | Jan 8, 2016 | — |
| DEFA14A | Additional proxy material | Jan 7, 2016 | — |
| DEFA14A | Additional proxy material | Dec 30, 2015 | — |
| DEFA14A | Additional proxy material | Dec 29, 2015 | — |
| DEFA14A | Additional proxy material | Dec 23, 2015 | — |
| DEFA14A | Additional proxy material | Dec 4, 2015 | — |
| DEFA14A | Additional proxy material | Nov 19, 2015 | — |
| DEFA14A | Additional proxy material | Nov 2, 2015 | — |
| DEFA14A | Additional proxy material | Apr 30, 2015 | — |
| DEF 14A | Proxy statement | Apr 30, 2015 | Jun 9, 2015 |
| DEFA14A | Additional proxy material | Apr 30, 2014 | — |
| DEF 14A | Proxy statement | Apr 30, 2014 | Jun 10, 2014 |
| DEFA14A | Additional proxy material | Apr 30, 2013 | — |
| DEF 14A | Proxy statement | Apr 30, 2013 | Jun 11, 2013 |
Showing 40 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PBYI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Los Angeles, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1401667
- Former names
- INNOVATIVE ACQUISITIONS CORP (until Oct 4, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.